Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Pfizer: clinical trial collaboration & supply agreement (Sep 2025); Pfizer supplies elranatamab at no cost; company sponsors and conducts the trial
Indications
Multiple myeloma(Phase 1)
Status note IKZF1/3 degrader (MonoDAC). Most advanced product candidate per filing. Ongoing/planned Phase 1b trial in combination with dexamethasone and elranatamab in second-line or later multiple myeloma.
CFT8919
Phase 1 · ActiveModality: protein degrader
Target EGFR (L858R mutant)
Partnerships Betta Pharma: exclusive Greater China license (May 2023); $10M upfront, up to $357M milestones; C4 retains rest-of-world rights
Indications
not disclosed(Phase 1)
Status note Allosteric, mutant-selective BiDAC degrader of EGFR L858R (target/modality per 10-K fallback). Phase 1 trial referenced in primary; Betta Pharma conducts clinical development in Greater China, C4 retains ex-Greater China rights.
Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.